Table 2.
Clinical and pathologic features including HPV status for patients with metastatic HNSCC to the brain
| case | gender | age | 1° site | 1° stage | lung mets | # brain mets | brain met free survival (months) | HPV status | |
|---|---|---|---|---|---|---|---|---|---|
| P16 IHC | HPV16 ISH | ||||||||
|
| |||||||||
| 1 | M | 61 | BOT | T3N2bM0 | yes | 1 | 57 | + | + |
| 2 | M | 46 | BOT | T3N1M0 | yes | 1 | 22 | + | + |
| 3 | M | 53 | tonsil | T4N2bM0 | yes | 9 | 53 | + | + |
| 4 | M | 65 | BOT | T2N1MX | yes | 2 | 37 | + | + |
| 5 | M | 59 | larynx | T4aN2cMO | yes | 1 | 8 | − | − |
| 6 | M | 42 | tonsil | unknown | yes | 1 | 27 | − | − |
| 7 | M | 55 | unknown | unknown | yes | 1 | 52 | − | − |
BOT, base of tongue; mets, metastases; IHC, immunohistochemistry; ISH, in situ hybridization